Skip to content
Wire frame hand with test tube

Preclinical DILI Risk Assessment Strategies: Bile Acid-Dependent Hepatotoxicity & Mitochondrial Toxicity Assays

  • Webinar

As part of this year’s SOT Annual Meeting and ToxExpo, we will be including a special presentation as part of our virtual booth experience. So if you are planning to attend the event (March 12th-26th, find details here), be sure to visit virtual booth #2031.

If you will not be attending the SOT Meeting & ToxExpo, you can register below to receive on-demand access to the recorded presentation during the conference.

Abstract

Hepatotoxicity studies in preclinical development provide key data to de-risking a compound early or screening compounds out that would not meet regulatory scrutiny. Drug-Induced Liver Injury (DILI) incidents account for more than 10% of all cases of acute liver failure, posing a major clinical and regulatory challenge. While the cause of DILI is multifactorial and difficult to predict, there are known mechanisms that can be screened for in preclinical development using in vitro methods.

Two of these mechanisms are cholestasis and mitochondrial toxicity.

In cholestasis, bile acid accumulation leads to hepatocyte cytotoxicity, reducing the liver’s ability to function and causing tissue damage. Mitochondrial toxicity impacts cells’ energy source and can further inhibit function. Our cholestatic DILI assessments, including a functional assay and an ROC analysis, and mitochondrial toxicity assay can help you evaluate your compound’s risk of hepatotoxicity.

Keypoints covered will include:

Download the Slides

About the Presenter:

Madison Knapp is a Marketing Communications Specialist, focused on creating educational and scientific content to communicate SEKISUI XenoTech’s expertise in drug metabolism and drug interaction studies. She received her BS from the University of Missouri – Columbia and became SEKISUI XenoTech’s Scientific Communications Coordinator in 2019 after serving in similar positions at CropLife America, Bond Life Sciences Center and the CAFNR Office of Communications.